DCvax: A promising advancement in oncology for the treatment of glioblastoma.

Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment. Keywords: Glioblastoma; DCVax; Primary Brain Tumor EN Glioblastoma DCVax Primary Brain Tumor 1 2 2 05/30/23 20230526 NES 230526 B Dear Editor, b Glioblastoma is a malignant neoplasm of the central nervous system that arises from glial cells, primarily astrocyctes and is characterized by poorly differentiated, fusiform, round or pleomorphic astrocyctic cells with marked nuclear atypical and brisk mitotic activity.[1] Despite advances in early diagnosis and comprehensive treatments, there is nearly 100% recurrence rate and dismal patient survival.[2] According to researchers, more than 13,000 Americans are diagnosed with Glioblastoma annually, causing significant morbidity and mortality. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial: a phase 3 prospective externally controlled cohort trial. [Extracted from the article]

Copyright of Rare Tumors is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)